Exelixis registers Phase 2 trial pairing zanzalintinib with pembrolizumab in NSCLC
New Phase 2 study, STELLAR-202, will test maintenance therapy in metastatic squamous non-small cell lung cancer.
Exelixis added a new trial registration to ClinicalTrials.gov during the period covered.
- A Phase 2, single-arm, multicenter trial called STELLAR-202 (NCT07845786) will test zanzalintinib combined with pembrolizumab as first-line maintenance therapy in metastatic squamous non-small cell lung cancer, sponsored by Exelixis.1 The study status is listed as not yet recruiting, with an estimated start date of December 15, 2026 and planned enrollment of 60 participants.1 The primary outcome measure is Progression-Free Survival (PFS) at 6 Months (PFS-6) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as Assessed by Investigator.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.